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Abstract
Recent positron emission tomography (PET) studies have demonstrated the accumulation of tau PET tracer in the
affected region of progressive supranuclear palsy (PSP) cases. To confirm the binding target of radiotracer in PSP,
we performed an imaging-pathology correlation study in two autopsy-confirmed PSP patients who underwent
[18F]THK5351 PET before death. One patient with PSP Richardson syndrome showed elevated tracer retention in the
globus pallidus and midbrain. In a patient with PSP-progressive nonfluent aphasia, [18F]THK5351 retention also was
observed in the cortical areas, particularly the temporal cortex. Neuropathological examination confirmed PSP in
both patients. Regional [18F]THK5351 standardized uptake value ratio (SUVR) in antemortem PET was significantly
correlated with monoamine oxidase-B (MAO-B) level, reactive astrocytes density, and tau pathology at postmortem
examination. In in vitro autoradiography, specific THK5351 binding was detected in the area of antemortem
[18F]THK5351 retention, and binding was blocked completely by a reversible selective MAO-B inhibitor, lazabemide,
in brain samples from these patients. In conclusion, [18F]THK5351 PET signals reflect MAO-B expressing reactive
astrocytes, which may be associated with tau accumulation in PSP.
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Introduction
Tau positron emission tomography (PET), which
provides the topographic distribution of tau aggregates
in the brain, would be useful for the diagnosis of
Alzheimer’s disease (AD) and for the assessment of tau
burden in the clinical trials of antidementia drugs. Most
studies on a tau PET radiopharmaceutical ([18F]AV1451)
showed a robust difference between the control subjects
and the patients with AD [16]. Regional distribution of
[18F]AV1451 was correlated with tau neuropathology in
MAPT R406W mutation carriers [37]. Tau PET also has
been considered potentially useful for antemortem as-
sessment of non-AD tauopathies, such as progressive
supranuclear palsy (PSP), corticobasal degeneration
(CBD), and some variants of frontotemporal lobar de-
generation (FTLD) [44]. [18F]AV1451 PET studies have
shown elevated tracer retention where tau pathology
was observed frequently in patients with PSP and CBD.
However, several reports have highlighted the discrepan-
cies between antemortem PET and postmortem in vitro
binding studies, particularly in non-AD tauopathies. In
vitro autoradiography validation studies demonstrated
that [18F]AV1451 failed to bind to 4-repeat tau lesions in
PSP and CBD [18, 24, 38]. Recent progress in the devel-
opment of second-generation tau tracers successfully re-
duced the off-target binding in the basal ganglia and
brainstem. However, to our knowledge, no tau PET ra-
diopharmaceutical has been fully validated against
neuropathology to date [23, 43]. [18F]THK5351 was one
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of the first-generation tau PET radiotracers that was de-
signed originally to detect tau aggregates in the form of
PHF-tau in AD [11]. Clinical PET studies in PSP and
CBS patients have demonstrated prominent
[18F]THK5351 retention [2, 14, 19] in the midbrain and
basal ganglia where tau pathology was observed fre-
quently at autopsy [20, 45]. [18F]THK5351 binding in
these areas is associated closely with disease progression
because the amount of tracer retention was correlated
positively with clinical severity of PSP [2]. However, re-
cent studies have suggested the existence of off-target
binding to monoamine oxidase-B (MAO-B). A single
oral dose of selegiline, a selective irreversible MAO-B in-
hibitor, substantially reduced [18F]THK5351 binding in
the brain of patients with PSP as well as AD [29]. In an
autopsy case of AD, regional [18F]THK5351 binding was
correlated significantly with MAO-B density as well as
tau level. Therefore, [18F]THK5351 PET signal reflects
the combination of tau pathology and reactive astrocytes
in the AD brain [10]. However, what an [18F]THK5351
PET signal reflects in the PSP brain remains unclear.
We examined imaging-pathology correlation in two
autopsy-confirmed PSP patients who showed prominent
tracer retention on an antemortem [18F]THK5351 PET
scan.
Materials and methods
The ethics committee of the Tohoku University Gradu-
ate School of Medicine approved this study, and in-
formed consent for neuroimaging and autopsy was
obtained for each subject.
PET and MRI scans and image analyses
PET images were acquired using an Eminence
STARGATE PET scanner (Shimadzu, Kyoto, Japan).
After intravenous injection of [18F]THK5351 (185 MBq)
or [11C]PiB (296 MBq), dynamic PET images were ob-
tained for 60 ([18F]THK5351) or 70 ([11C]PiB) minutes.
T1-weighted magnetic resonance images (MRI) were ob-
tained using a SIGNA 1.5-Tesla machine (General
Electric, Milwaukee, WI, USA) according to a previously
described method [14]. Standardized uptake value (SUV)
images of [18F]THK5351 (40–60 min after injection) and
[11C]PiB (50–70 min after injection) were obtained by
normalizing tissue radioactivity concentration by injected
dose and body weight. The regional SUV-to-cerebellar
cortex SUV ratio (SUVR) was used as an index of tracer
retention. SPM12 software (SPM12; Wellcome
Department of Imaging Neuroscience, UCL, London, UK)
was used to coregister the PET images on the MRI image.
PMOD Ver. 3.7 software (PMOD Technologies GmbH,
Zurich, Switzerland) was used to draw regions of interest
(ROIs) on the coregistered MRI image.
Brain tissue samples
The left hemisphere was immersed in 10% formalin
for histology. The brain portions were frozen on
powdered dry ice for biochemical analyses and
unfixed tissue-based assays. Tissue sections of
paraffin-embedded blocks were stained with Luixol
fast blue and hematoxylin-eosin. Selected sections
were stained with anti-tau AT8 (1:20; Innogenetics,
Ghent, Belgium), anti-β-amyloid 4G8 (1:10,000;
BioLegend [Signet], San Diego, CA USA),
anti-α-synuclein P-syn/81A (1:100, BioLegend
[Covance]), anti-TDP43 pS409/410–1 (1:5000; Cosmo
Bio, Tokyo, Japan), and anti-GFAP 6F2 (1:100;
Agilent [Dako], Santa Clara, CA, USA) antibodies.
Brain slices 12 μm thick were generated with a cryo-
stat (Microm HM560; Thermo Scientific, Waltham,
MA, USA) using − 20 °C chamber and − 15 °C ob-
ject temperatures. The sections were transferred to
Matsunami Adhesive Slide (MAS)–coated glass slides
(Matsunami Glass Ind., Ltd., Osaka, Japan). After
drying, the sections were stored at − 80 °C. In sub-
ject 1, brain homogenates (0.1 mg/mL) additionally
were prepared in phosphate-buffered saline (PBS)
and stored at − 80°C until experimental use.
Quantification of tau and glial fibrillary acidic protein
(GFAP) immunoreactivity
Microscopic images from each section of
paraffin-embedded blocks were captured and a threshold
of optical density was obtained by Image J software
(National Institutes of Health [NIH], Bethesda, MD,
USA). Tau and GFAP immunoreactivity was defined as
total percentage of area covered by tau and GFAP im-
munostaining in each ROI.
In vitro autoradiography of [18F]THK5351
The brain sections were dried and were dipped in PBS
for a total of 25 min and, then, preincubated in PBS con-
taining 1% bovine serum albumin (BSA). Then, the brain
sections were incubated for 30 min at room temperature
with [18F]THK5351 (370 kBq/mL). After incubation, the
sections were washed sequentially with PBS containing
1% BSA for 5 min, followed by PBS for 5 min twice. The
dried sections were exposed to an imaging plate (BAS IP
MS 2025 E; GE Healthcare, Little Chalfont, UK) over-
night. Autoradiographic images were obtained from
Typhoon FLA-9500 (GE Healthcare). To account for the
binding to MAO-B in brain tissues, the reaction was in-
cubated in the presence of MAO-B inhibitor,
Lazabemide (1 μM). After post-fixation in 4% parafor-
maldehyde for 30 min, adjacent frozen sections were im-
munostained with anti-tau AT8, anti-MAO-B (1:400,
Sigma-Aldrich Corp., St. Louis, MO, USA), and
anti-GFAP 6F2 antibodies.
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In vitro binding assay of [3H]THK5351
The reaction mixture contained [3H]THK5351 (1 nM;
specific activity, 2.96 TBq/mmol; radiochemical purity,
98.9%; Sekisui Medical, Inc., Tokyo, Japan) and brain
homogenates (0.5 μg), in a final volume 200 μL.
Nonspecific binding was defined in the presence of
2 μM unlabeled THK5351. The mixture was incubated
at room temperature for 2 h, and separation of bound
from free radioactivity was achieved by filtration under
reduced pressure (Multiscreen HTS Vaccum Manifold,
Multiscreen HTS 96-well 0.65 μm filtration plate;
Millipore, Billerica, MA, USA), followed by three washes
with PBS containing 0.1% BSA. The filters were incu-
bated in 2 mL scintillation fluid (Emulsifier-Safe; Perkin
Elmer, Boston, MA, USA), and a β counter (LS6500 li-
quid scintillation counter; Beckman Coulter, Brea, CA,
USA) was used to count the radioactivity.
Semiquantification of PHF-tau by immunoblotting
Immunoblotting for PHF-tau was performed according
to a previously reported protocol [39]. After centrifuga-
tion (20,000 g, 15 min, 4 °C) of brain homogenates, the
resulting pellet was dissolved in extraction buffer con-
taining 10 mM Tris-HCl (pH 7.5), 0.8 M NaCl, 10% su-
crose, 1 mM ethylene glycol-bis β-aminoethyl ether
(EGTA), 2% sarkosyl, and then incubated for 30 min at
37 °C. The supernatants were collected after centrifuga-
tion at 20,000 g for 10 min at 25 °C. After ultracentrifu-
gation (100,000 g, 20 min, 25 °C), the pellets were
washed with 0.5 mL sterile saline and solubilized in so-
dium dodecyl sulfate (SDS)–sample buffer and, then,
run on a 5–20% gradient polyacrylamide gel (SuperSep™
Ace; Wako, Osaka, Japan). Proteins were transferred to
polyvinylidine fluoride (PVDF) membrane, blocked by
incubation with 3% gelatin (Wako) for 10 min at 37 °C,
followed by overnight incubation at room temperature
with the anti-tau monoclonal antibody T46 (1:2000,
Thermo Fisher Scientific), biotinylated anti-mouse sec-
ondary antibody, ABC complex (Vector Laboratories,
Burlingame, CA, USA) and developed with
diaminobenzidine and nickel chloride. For semiquantifi-
cation of sarkosyl-insoluble tau, the three dominant
bands (68, 64, and 60 kDa) were quantified by ImageJ
software (Additional file 1: Figure S1). Sarkosyl-insoluble
tau (PHF-tau) was expressed as ratio using cerebellum
as reference.
Quantification of MAO-B and GFAP by enzyme-linked
immunosorbent assay (ELISA)
Brain MAO-B levels were quantified using a human
MAO-B ELISA kit (Ab157393, Abcam, Cambridge, UK)
with MAO-B standard (M7441, Sigma-Aldrich Corp.).
Extraction of MAO-B was performed according to the
manufacturer’s instructions. For the quantification of
GFAP, brain homogenates were extracted with Tris-HCl
buffer containing 0.1% Triton-X as described previously
[13]. A human GFAP ELISA kit (BioVendor, Asheville,
NC, USA) was used to quantify the GFAP levels.
Statistical analysis
Spearman rank correlation coefficients were calculated
to examine the association between radiotracer binding,
histopathology, and biochemical data. Statistical signifi-
cance was defined at P < 0.05. GraphPad Prism software
(GraphPad, San Diego, CA, USA) was used to perform
this analysis.
Results
Case reports
Subject 1
An 84-year-old right-handed male presented with mem-
ory disturbance and disorientation. One year later, stand-
ing and gait became unstable with progression of
extrapyramidal signs and PSP was diagnosed clinically.
PET scans were performed 2 years after the diagnosis of
PSP. At the time of the PET scan, he was bedridden and
the Mini-Mental State Examination (MMSE) score was
1 of 30. Neurologic examinations revealed limited verti-
cal eye movement. The PSP rating scale score was 82. A
brain MRI showed significant midbrain atrophy. A typ-
ical “hummingbird sign” was observed in the sagittal
section. He died of aspiration pneumonia 295 days after
the PET scan. Detailed clinical information has been de-
scribed previously [14].
Subject 2
A 73-year-old right-handed male presented with mem-
ory disturbance. Mild cognitive impairment was diag-
nosed clinically 3 years after the first symptoms
appeared. He gradually presented with speech impair-
ment, stereotypical behavior, and change of food prefer-
ence, and progressive nonfluent aphasia (PNFA) was
diagnosed. We did not perform DNA sequencing to
confirm a mutation in the MAPT gene. One year later,
he presented with unstable gait and was prone to falls.
At the PET scan, he was bedridden and the MMSE score
was 1 of 30. An MRI showed diffuse brain atrophy
prominent in the right anterior temporal, hippocampus,
amygdala, and caudate nuclei. He died of aspiration
pneumonia 79 days after PET scan.
[18F]THK5351 and [11C]PiB PET scans
Figure 1 shows the [18F]THK5351 PET images from the
two subjects. Images from a cognitively normal individ-
ual are shown for comparison at the bottom (Fig. 1).
Subject 1 showed significant [18F]THK5351 retention in
the globus pallidus and midbrain. Mild tracer retention
was observed also in the other cortices, including
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parahippocampal and inferior temporal gyri. Subject 2
showed prominent [18F]THK5351 retention in the para-
hippocampal and inferior temporal gyri, as well as the
globus pallidus and midbrain. No remarkable retention
of [11C]PiB was observed in the neocortex in both of the
subjects (data not shown).
Neuropathological examination
Brain weight in subject 1 was 1580 g. Autopsy revealed
severe atrophy in the midbrain tegmetum and pons, and
subthalamic nucleus, and relatively mild atrophy in the
frontal cortex, but not in the basal ganglia. Neuropatho-
logical examination revealed tau pathology in neuronal
and glial cells consistent with PSP. Globose tangles were
observed in the midbrain, pons, medulla, subthalamic
nucleus, and nucleus basalis of Meynert. Moderate num-
bers of tufted astrocytes were observed also in the
amygdala, motor cortex, and superior frontal gyrus.
Neurofibrillary tangles were observed in the entorhinal
cortex and subiculum, which corresponded to
age-related Braak stage II [1]. The tau immunoreactivity
density appeared greatest in the medial temporal re-
gions, followed by the basal ganglia and frontal cortex.
Small cerebral infarctions were observed in the putamen
and the cerebellum. Gliosis and neuronal loss were ob-
served also in the substantia nigra. However, amyloid-β,
α-synuclein, and TDP-43 pathology were absent in this
case. These characteristics were consistent with the diag-
nosis of definite PSP.
Brain weight in subject 2 was 920 g. Autopsy revealed
severe atrophy in bilateral temporal lobes, including the
hippocampus and amygdala. Brain atrophy was
obviously observed in the tegmentum of the midbrain
and pons. There was neuronal loss in the pigmented
neurons of the substantia nigra and locus coeruleus.
Brain atrophy was observed also in the globus pallidus,
hypothalamic nucleus, and cerebellar dentate nucleus.
AT8 immunostaining revealed abundant tau burden, in-
cluding neurofibrillary tangles, globose tangles, tufted
astrocytes, coiled bodies, and neuropil threads in the
temporal, cingulate, frontal, striatum, globus pallidus,
and subthalamic nucleus. In addition, thorn-shaped as-
trocytes, typical in aging-related tau astrogliopathy, were
observed in the temporal lobe gray and white matter
[21]. Sparse amyloid plaques were observed in the cere-
bral cortex (Thal phase for Aβ plaques: 2, CERAD:
Sparse). Both α-synuclein and TDP-43 pathology were
absent in this case. Gliosis was severe in the bilateral
hippocampus and amygdala. Astrocytosis with neuronal
loss was prominent in the temporal cortex, followed by
the frontal and cingulate cortices. Three- and
four-repeat tau-immunohistochemistry studies, respect-
ively, revealed that these tau lesions were composed of
four-repeat tau. The distribution, isoform, and
morphology of tau immunoreactive lesions were consist-
ent with atypical PSP [17], which was diagnosed as
PSP-FTD.
In vivo–in vitro correlation analyses
Biochemical analysis revealed the presence of
sarkosyl-insoluble tau (68 and 64 kDa), corresponding to
4-repeat tau protein in both cases (Additional file 1:
Figure S1). In subject 1, sarkosyl-insoluble tau was high
in the parahippocampal gyrus and hippocampus,
Subject 1
(PSP-RS)
Subject 2
(PNFA)
Cognitively 
normal
Fig. 1 [18F]THK5351 PET images from two study subjects and a cognitively normal subject. The scale indicates SUVR range from 0 to 4
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moderate in the globus pallidus and putamen, and low
in other areas (Fig. 2a). The parahippocampal gyrus con-
tained 3- (60 kDa band) and 4-repeat tau, suggesting
that they are age-related tau. AT8 immunohistochemis-
try was positive in the brain sections from the same tis-
sue (data not shown). In subject 1, in vivo
[18F]THK5351 binding was correlated significantly with
sarkosyl-insoluble tau levels determined by Western blot
analysis (r = 0.67, P = 0.039; Fig. 2b). In addition, we
found a strong correlation between in vivo [18F]THK5351
binding and MAO-B levels (r = 0.78, P = 0.0096; Fig. 2c).
A significant positive correlation was observed also
between in vivo [18F]THK5351 binding and GFAP
level (r = 0.67, P = 0.039; Fig. 2d). In vitro
[3H]THK5351 binding assay using brain homogenates
also demonstrated a strong correlation between in
vivo [18F]THK5351 retention and in vitro tracer bind-
ing in subject 1 (r = 0.92, P = 0.005; Fig. 2e). Tau and
GFAP immunoreactivities in the brain sections were
measured quantitatively for correlation analysis be-
tween in vivo tracer retention and histopathology
(Fig. 3). We observed positive correlation trends
between in vivo [18F]THK5351 retention and tau
loads (r = 0.48, P = 0.06), and between in vivo
[18F]THK5351 retention and GFAP immunoreactivity
(r = 0.49, P = 0.05).
In subject 2, in vivo [18F]THK5351 binding was
correlated significantly with tau-immunohistochemistry
using AT8 antibody (r = 0.48, P = 0.037; Fig. 4b). Further-
more, in vivo [18F]THK5351 retention was correlated
positively with the density of GFAP immunoreactive
astrocytes (r = 0.64, P = 0.0033).
In vitro autoradiography
In vitro autoradiography of [18F]THK5351 in frozen sec-
tions demonstrated high tracer binding in the globus
pallidus as well as putamen in subject 1 and in the
frontal cortex in subject 2 (Fig. 5), which was consistent
with in vivo PET results (Fig. 1). These bindings were
displaced completely after treatment with MAO-B in-
hibitor, Lazabemide [10]. The spatial pattern of
[18F]THK5351 binding was similar to that of MAO-B
immunostaining, suggesting that the target of
[18F]THK5351 binding was MAO-B–positive astrogliosis
rather than the tau aggregates in the PSP brain.
Discussion
Tremendous efforts have been made to develop
tau-selective PET radiopharmaceuticals. The
first-generation tau PET tracers, such as [11C]PBB3,
[18F]AV1451, and [18F]THK5351, have shown accu-
mulation in the predilection site for tau deposition.
Tau PET imaging recapitulated topographical re-
gional distribution patterns similar to those reported
by Braak staging of tau pathology at autopsy [44].
However, they showed nonnegligible off-target
68
64
60
kDa
T46 (anti-tau C-terminus)
Fr Pa Oc HiP PHG FuG ITG STG Put GP Cb
ba
c d e
Fig. 2 Neuroimaging, biochemical, in vitro binding correlations in subject 1 (PSP-RS). a Immunoblot analysis of sarkosyl-insoluble tau; 11 regions
(Fr, frontal cortex; Pa, parietal cortex; Oc, occipital cortex; HiP, hippocampus; PHG, parahippocampal gyrus; FuG, fusiform gyrus; ITG, inferior
temporal gyrus; STG, superior temporal gyrus; Put, putamen; GP, globus pallidus; Cb, Cerebellum) detected by T46 (anti-tau C-terminus). b
[18F]THK5351 SUVR plotted against sarkosyl-insoluble tau level (%cerebellum). c [18F]THK5351 SUVR plotted against MAO-B level. d [18F]THK5351
SUVR plotted against GFAP level. e [18F]THK5351 SUVR plotted against in vitro [3H]THK5351 binding
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binding [4, 11, 27]. A recent human blocking study
using selegiline demonstrated binding of [18F]THK5351 to
MAO-B [29]. Furthermore, the regional [18F]THK5351
binding was correlated significantly with density of
MAO-B in our autopsy case of AD [10]. In this study, we
expanded the imaging-pathology correlation analysis to
autopsy-confirmed PSP cases showing two different
clinical phenotypes, Richardson syndrome (PSP-RS)
and PNFA.
A patient with PSP-RS showed remarkable
[18F]THK5351 retention in the globus pallidus and mid-
brain [2, 14]. The spatial distribution of [18F]THK5351
retention in this patient was similar to the topographical
distribution of tau pathology in cases of classic PSP-RS
[45]. Postmortem examination of this patient confirmed
the existence of 4-repeat tau aggregates in these regions.
However, imaging-pathology correlation analysis indi-
cated a significant correlation between in vivo
[18F]THK5351 retention and MAO-B level. Further-
more, in vitro autoradiography demonstrated that
[18F]THK5351 binding in the globus pallidus was dis-
placed by the MAO-B inhibitor, suggesting that
[18F]THK5351 mainly binds to the MAO-B rather than
the 4-repeat tau aggregates. In our previous study using
paraffin-embedded fixed brain sections, we observed
specific binding of [18F]THK5351 to tufted astrocytes
po
L CbR GP Pons MidbrainR HipR SFG R PCG
scale bar: 100 µm
a b c d e f g
h i j k l m n
Fig. 3 Neuroimaging-histopathologic correlations in subject 1 (PSP-RS). a–n Microscopic examination of tau pathology (a–g) and astrogliosis (h–n).
R SFG, right superior frontal gyrus (a, n); R PCG, right posterior cingulate gyrus (b, i); R HiP, right hippocampus (c, j); R GP, right globus pallidus (d, k);
Pons (e, l); Midbrain (f, m); and L Cb, left cerebellar cortex (g, n). [18F]THK5351 SUVR plotted against AT8 tau–positive areas (o) and GFAP-positive
areas (p)
Ishiki et al. Acta Neuropathologica Communications  (2018) 6:53 Page 6 of 10
and neurofibrillary tangles in the PSP brain [14]. How-
ever, the fixation of tissues and use of alcohol in the dif-
ferentiation process may affect the tracer binding (i.e.,.,
diminishing the natural binding sites and/or yielding
artificial binding sites) in in vitro autoradiography exper-
iments. In this study, we performed in vitro autoradio-
graphs of fresh-frozen sections without using alcohol
and found a substantial amount of tracer binding to
MAO-B. Fresh-frozen section results showed good
agreement with antemortem [18F]THK5351 PET ana-
lysis. These results highlighted the importance of appro-
priate experimental procedures in the validation of PET
radiopharmaceuticals.
[18F]AV1451 PET studies in PSP cases have shown
high tracer retention in the globus pallidus and mid-
brain, as observed in [18F]THK5351 PET. However, the
postmortem in vitro autoradiography did not show any
significant binding of [18F]AV1451 in these brain regions
[18, 24, 38]. The discrepancy between in vitro and in
vivo PET results may be explained also by the same
technical problems as those observed in THK5351. Most
of these studies used high concentrations of ethanol in
the differentiation process of autoradiography [5, 25, 33,
46]. High binding affinity of [18F]AV1451 to monoamine
oxidases (MAO-A and MAO-B for Kd = 1.6 nM and
21 nM, respectively) was observed in in vitro binding
po
R CbL STG L ITG R PCG R HiP R ITG R STG
scale bar: 100 µm
a b c d e f g
h i j k l m n
Fig. 4 Neuroimaging-histopathologic correlations in subject 2 (PNFA). a–n Microscopic examination of tau pathology (a–g) and astrogliosis (h–n).
L STG, left superior temporal gyrus (a, n); L ITG, left inferior temporal gyrus (b, i); R PCG, right posterior cingulate gyrus (c, j); R HiP, right
hippocampus (d, k); R ITG, right inferior temporal gyrus (e, l); R STG, right superior temporal gyrus (f, m); and L Cb, left cerebellar cortex (g, n).
[18F]THK5351 SUVR plotted against AT8 tau–positive areas (o) and GFAP-positive areas (p)
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assay [42]. [18F]AV1451 binding to MAO may be over-
looked by the use of ethanol. Retrospective investigation
of [18F]AV1451 PET in patients with Parkinson’s disease
showed no significant difference between conditions be-
fore and after treatment with irreversible MAO-B inhibi-
tors (selegiline and rasagiline) [9]. Therefore, the
dominant off-target binding substrates of [18F]AV1451
would be MAO-A or other unknown molecules.
We observed a significant correlation between tau
pathology and GFAP in both of our subjects. Tau path-
ology in PSP includes neurofibrillary tangles, tufted as-
trocytes, coiled bodies, and threads pathology [45]. A
postmortem study reported that the density of GFAP
correlated with that of neurofibrillary tangles, but not
with tufted astrocytes in PSP, suggesting the greater con-
tribution of neurofibrillary tangles to astrogliosis in PSP
[40]. MAO-B is expressed dominantly in the mitochon-
drial outer membrane of astrocytes. Since elevation of
MAO-B levels in the brain has been implicated in sev-
eral neurodegenerative diseases, MAO-B is an attractive
target as a molecular imaging marker of astrogliosis [7].
Recently, a postmortem study in parkinsonian condi-
tions, including PSP, demonstrated that MAO-B levels
elevated remarkably in the midbrain of PSP and
positively correlated with astroglial markers, such as
GFAP, vimentin, and Hsp27 [41], which was consistent
with our observation. MAO-B PET imaging using
[11C]L-deprenyl-D2 showed elevated tracer retention in
the brain of several neurodegenerative diseases including
AD [6, 15, 34]. Other investigators have reported the ele-
vation of tracer binding in prodromal AD, but not in
symptomatic AD [3, 30, 36]. However, many postmor-
tem studies have shown the elevation of MAO-B levels
in the postmortem brains of AD [8, 26, 35]. As discussed
previously [41], this discrepancy might be explained by
the low sensitivity of [11C]L-deprenyl-D2 PET. Recently,
second-generation MAO-B PET tracers, such as
[11C]SL25.1188, have been developed and showed
reversible binding to MAO-B [31, 32]. Furthermore, the de-
velopment of [18F]labeled PET tracers is ongoing [12, 28].
GFAP AT8
+Lazabemide
+Lazabemide18F-THK5351
18F-THK5351
GFAP
MAO-B
MAO-B AT8
a
b
Fig. 5 In vitro autoradiography of [18F]THK5351 and immunohistochemistry (MAO-B, GFAP, AT8-tau) in frozen sections from subjects. a Basal
ganglia from subject 1 and b frontal cortex from subject 2. The specific binding to MAO-B was confirmed by a reversible MAO-B inhibitor,
Lazabemide. Scale bars: 5 mm
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Our study strongly supported that [18F]THK5351 PET
dominantly reflected the binding to MAO-B in patients
with PSP. Therefore, [18F]THK5351 PET would be useful
for in vivo assessment of astrogliosis in PSP. Future re-
search should proceed with development of PET tracers for
selective detection of astrogliosis and sensitive detection of
4-repeat tau in the human brain. -
In PSP-RS cases, ischemic changes observed in the pu-
tamen might induce reactive astrocytes. Recently, react-
ive astrocytes have been categorized into two different
types depending on the gene expression: A1 astrocytes
highly upregulated many classical complement cascades
and are toxic as observed in neuroinflammation; A2 as-
trocytes upregulated many neurotrophic factors and are
protective as observed in ischemia [22]. The GFAP
showed elevated expression in both reactive astrocytes.
[18F]THK5351 PET signal in the putamen of PSP-RS
cases may reflect elevation of MAO-B levels induced by
ischemia. Further studies are required to clarify MAO-B
expression profiles in reactive astrocytes subtypes.
Conclusions
Our imaging-pathology validation study demonstrated
the binding of [18F]THK5351 to MAO-B–positive astro-
gliosis in the PSP brain. Therefore, [18F]THK5351 PET
may be useful to assess astrocytosis in non-AD
tauopathies.
Additional file
Additional file 1: Figure S1. Immunoblot analysis of sarkosyl-insoluble
tau in the study subject and an AD case detected by T46 (anti-tau
C-terminus). The study subjects contained dominantly 4R tau (64- and 68-kDa
tau). (PPTX 334 kb)
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